Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,290 across all filing types
Latest filing 2020-11-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
招商证券关于安图生物使用募集资金置换预先投入的自筹资金的核查意见
Regulatory Filings
2020-11-16 Chinese
关于使用募集资金置换预先投入自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of raised funds from a non-public stock issuance to replace previously self-raised funds invested in projects. It details the amount of funds raised, the projects involved, approvals from regulatory bodies, and opinions from auditors, sponsors, independent directors, and the supervisory board. The document references compliance with the Shanghai Stock Exchange's rules on the management and use of raised funds. The content focuses on the company's capital management and financing activities, specifically the replacement of self-raised funds with raised capital. It does not contain financial statements or comprehensive financial performance data, nor is it a report or presentation. The document length is under 5,000 characters and is a formal announcement of a financing-related activity. Therefore, it fits best under the category 'Capital/Financing Update' (CAP).
2020-11-16 Chinese
章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of 郑州安图生物工程股份有限公司, which is a legal and governance document outlining the company's organizational structure, shareholder rights, board responsibilities, and other corporate governance matters. It includes detailed chapters on shares, shareholders, board of directors, management, financial accounting, and procedures for shareholder meetings. This type of document is a governance framework rather than a financial report, earnings release, or announcement. It is not a report publication announcement or a regulatory filing in the sense of a compliance document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is the full governance document, not a brief announcement or summary.
2020-11-16 Chinese
招商证券关于安图生物增加部分募投项目实施主体并使用募集资金向全资子公司提供借款实施募投项目的核查意见
Regulatory Filings
2020-11-16 Chinese
独立董事关于公司第三届董事会第二十次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent director's opinion on several proposals related to the use of raised funds by the company, including replacement of self-raised funds with raised funds, cash management of idle raised funds, and providing loans to subsidiaries for investment projects. It references compliance with regulatory guidelines and approval procedures but does not contain financial statements or detailed financial results. The document is a formal opinion related to board meeting matters but does not announce changes in board or management personnel. It is not a full financial report, earnings release, or regulatory filing of a different nature. Given the content focuses on board meeting related opinions on financial proposals, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA. Therefore, the classification is MANG with high confidence.
2020-11-16 Chinese
关于增加部分募投项目实施主体并使用募集资金向全资子公司提供借款实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the increase of some fundraising project implementation entities and the use of raised funds to provide loans to a wholly-owned subsidiary for project implementation. It details the non-public issuance of shares, the amount of funds raised, the investment projects, and the use of funds including loans to subsidiaries. It includes opinions from independent directors, the supervisory board, and the sponsor institution, confirming compliance with regulatory requirements and the appropriateness of the fund usage. The document is a formal announcement about capital raising and the use of proceeds, focusing on financing activities and capital structure changes. It is not a full financial report, audit report, or earnings release, nor is it a regulatory filing or a report publication announcement. Given the content and context, the document fits best under Capital/Financing Update (CAP). The document length is 4220 characters, which is relatively short but contains detailed information about fundraising and capital use, not just a brief notice or a report publication announcement.
2020-11-16 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.